Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Mouth cancer

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44364   clinical trials with a EudraCT protocol, of which   7388   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    82 result(s) found for: Mouth cancer. Displaying page 1 of 5.
    1  2  3  4  5  Next»
    EudraCT Number: 2005-000833-39 Sponsor Protocol Number: 35/04 Start Date*: 2004-10-22
    Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI
    Full Title: RANDOMIZED STUDY WITH POSTOPERATIVE RADIOTHERAPY AND CONCURRENT LOW DOSE CISPLATIN VS RADIOTHERAPY AND CONCURRENT CISPLATIN + FLUOROURACIL IN OPERATED HIGH RISK SQUAMOUS CELL CARCINOMA OF T...
    Medical condition: Head and neck cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061325 Oral neoplasm LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-018363-42 Sponsor Protocol Number: DOXERT1 Start Date*: 2010-09-15
    Sponsor Name:ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI - FONDAZIONE "G. PASCALE"
    Full Title: A phase II dose finding study of induction cisplatin, docetaxel and escalating doses of capecitabine followed by concurrent cetuximab and radiotherapy in locally advanced inoperable head and neck s...
    Medical condition: locally advanced inoperable head and neck squamous cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10026660 HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-012225-12 Sponsor Protocol Number: 64-Cu-ATSM-CC-02/2009 Start Date*: 2009-09-15
    Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
    Full Title: Role of 64Cu-ATSM PET/CT for the localization of hypoxic areas in head and neck cancer
    Medical condition: head and neck cancer. MEDRA code has not been found.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10026184 LLT
    9.1 10026161 LLT
    9.1 10025963 LLT
    9.1 10025923 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-000348-24 Sponsor Protocol Number: CVB2018-1 Start Date*: 2018-06-11
    Sponsor Name:Department of Otorhinolaryngology, Head and Neck Surgery
    Full Title: Mesenchymal stem cells for radiation-induced hyposalivation and xerostomia in previous head and neck cancer patients (MESRIX-II)
    Medical condition: The trial will include participants with Xerostomia (International Classification of Diseases-10: DQ 838A) who have been treated with raditherapy for a head and neck cancer prevoiusly.
    Disease: Version SOC Term Classification Code Term Level
    20.1 10017947 - Gastrointestinal disorders 10013781 Dry mouth PT
    20.0 10017947 - Gastrointestinal disorders 10048223 Xerostomia LLT
    20.0 100000004865 10039420 Salivary gland therapeutic procedures HLT
    20.0 10017947 - Gastrointestinal disorders 10039404 Salivary gland conditions HLGT
    21.1 10017947 - Gastrointestinal disorders 10039390 Salivary gland atrophy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2016-002082-65 Sponsor Protocol Number: 2016-002082-65 Start Date*: 2016-10-26
    Sponsor Name:Andreas Kjaer
    Full Title: Phase II trial: uPAR-PET/CT for prognostication in head- and neck cancer
    Medical condition: Head and neck cancer
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004856 10026660 Malignant oral cavity neoplasms HLT
    19.0 100000004864 10028801 Oropharyngeal, nasopharyngeal and tonsillar neoplasms malignant and unspecified HLT
    19.0 100000004864 10023826 Laryngeal neoplasms malignant HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-016668-35 Sponsor Protocol Number: HBO-CPH1 Start Date*: 2009-12-22
    Sponsor Name:Copenhagen University Hospital
    Full Title: Hyperbaric Oxygen - a new treatment modality in patients with salivary gland radiation injury
    Medical condition: Late radiation tissue injury to salivary glands
    Disease: Version SOC Term Classification Code Term Level
    12.0 10013781 Dry mouth LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-000978-53 Sponsor Protocol Number: DX10008 Start Date*: 2011-06-07
    Sponsor Name:Acacia Pharma Ltd
    Full Title: Randomised, double-blind, placebo-controlled Phase II proof-of-concept study of APD515 solution for oromucosal and oral administration for relief of xerostomia in patients with cancer
    Medical condition: Xerostomia
    Disease: Version SOC Term Classification Code Term Level
    14.0 10017947 - Gastrointestinal disorders 10048223 Xerostomia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2014-004349-29 Sponsor Protocol Number: 01-10-2014 Start Date*: 2015-04-01
    Sponsor Name:Rigshospitalet
    Full Title: Mesenchymal stem cells for radiation-induced xerostomia (MESRIX) in previous HPV-positive oropharyngeal head and neck cancer patients
    Medical condition: The study will include participants with xerostomi (International Classification of Diseases-10: DQ 838A) and oropharyngeal cancer (DC 10).
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10031103 Oropharyngeal cancer stage unspecified LLT
    17.1 100000004856 10048223 Xerostomia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2017-005015-13 Sponsor Protocol Number: C0947 Start Date*: 2018-05-18
    Sponsor Name:The Clatterbridge Cancer Centre NHS Foundation Trust
    Full Title: NICO - CA209-891: Neoadjuvant and adjuvant nivolumab as Immune Checkpoint inhibition in Oral cavity cancer
    Medical condition: Locally advanced squamous cell carcinoma of the oral cavity
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041857 Squamous cell carcinoma of the oral cavity PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2016-001256-22 Sponsor Protocol Number: GL0817-01 Start Date*: 2017-01-31
    Sponsor Name:Gliknik Inc
    Full Title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Determine the Safety and Efficacy of GL-0817 (with Cyclophosphamide) for the Prevention of Recurrence in HLA-A2+ Patients wi...
    Medical condition: Prevention of Recurrence in HLA-A2+ Patients with High-Risk Squamous Cell Carcinoma of the Oral Cavity
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004856 10026660 Malignant oral cavity neoplasms HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) ES (Prematurely Ended) PL (Prematurely Ended) HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-001361-12 Sponsor Protocol Number: FG001-CT-003 Start Date*: 2022-08-25
    Sponsor Name:FluoGuide A/S
    Full Title: An open-label, non-randomized, single center, single dose, exploratory phase II trial of FG001 (an imaging agent) for localization of oral and oropharyngeal squamous cell carcinoma
    Medical condition: Oral and oropharyngeal squamous cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041857 Squamous cell carcinoma of the oral cavity PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10031112 Oropharyngeal squamous cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2008-001354-41 Sponsor Protocol Number: UCLONCO08-001 Start Date*: 2008-04-11
    Sponsor Name:Cliniques Universitaires St Luc, Centre du Cancer
    Full Title: Neoadjuvant cetuximab monotherapy followed by surgery in squamous cell carcinoma of head and neck: phase I/II study
    Medical condition: patients with squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx newly diagnosed and eligible for surgery.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10041857 Squamous cell carcinoma of the oral cavity LLT
    9.1 10031112 Oropharyngeal squamous cell carcinoma LLT
    9.1 10021042 Hypopharyngeal cancer LLT
    9.1 10023856 Laryngeal squamous cell carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2013-003622-86 Sponsor Protocol Number: CA209-141 Start Date*: 2014-06-05
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: An Open Label, Randomized Phase 3 Clinical Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Platinum-refractory Squamous Cell Carcinoma of the Head and Neck (SCCHN)
    Medical condition: Squamous cell carcinoma of the head and neck
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066471 Squamous cell carcinoma of pharynx PT
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041857 Squamous cell carcinoma of the oral cavity PT
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10023856 Laryngeal squamous cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) GB (Completed) ES (Completed) DE (Completed) NL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2021-004189-37 Sponsor Protocol Number: HCQHNLcancer Start Date*: 2022-03-09
    Sponsor Name:OSPEDALE SAN RAFFAELE
    Full Title: Role of Hydroxychloroquine in therapeutic strategy of Head and Neck cancer and Non-small cell lung cancer
    Medical condition: Patients affected by Resectable Head and Neck (HN) cancer (only Squamous Cell Carcinoma of the oral cavity or larynx), or Resectable Non-small cell lung cancer (NSCLC, only Lung Squamous Cell Carci...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10078181 Laryngeal squamous cell carcinoma stage 0 LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10030964 Oral carcinoma LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10037352 Pulmonary carcinoma stage 0 LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025123 Lung squamous cell carcinoma stage II PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025122 Lung squamous cell carcinoma stage I PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-003484-23 Sponsor Protocol Number: Paccis-RCT_2005 Start Date*: 2010-04-14
    Sponsor Name:Universitätsklinikum Erlangen, Strahlenklinik insoweit handelnd für den Freistaat Bayern
    Full Title: Randomised phase-III-trial of simultaneous radiochemotherapy (RCT) of locally advanced head and neck cancer in the stages III and IV A-B: Comparing dose reduced RCT (63.6 Gy) with Paclitaxel/Cispla...
    Medical condition: Head and Neck cancer, Stage III-IV A-B
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10026518 Malignant neoplasm of supraglottis stage III LLT
    18.0 100000004864 10026185 Malignant neoplasm of oropharynx, unspecified LLT
    18.0 100000004864 10041862 Squamous cell carcinoma of the oral cavity stage III LLT
    18.0 100000004864 10041863 Squamous cell carcinoma of the oral cavity stage IV LLT
    18.0 100000004864 10041855 Squamous cell carcinoma of the hypopharynx stage IV LLT
    18.0 100000004864 10041854 Squamous cell carcinoma of the hypopharynx stage III LLT
    18.0 100000004864 10026519 Malignant neoplasm of supraglottis stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-004189-14 Sponsor Protocol Number: 24061 Start Date*: 2008-02-13
    Sponsor Name:EORTC
    Full Title: Randomized phase II feasibility study of Cetuximab combined with 4 cycles of TPF followed by platinum based chemo-radiation strategies
    Medical condition: Histologically proven newly diagnosed unresectable squamous cell carcinoma of the head and neck
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) HU (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-000373-21 Sponsor Protocol Number: IRX-22015A Start Date*: 2016-10-27
    Sponsor Name:IRX Therapeutics, Inc.
    Full Title: A Randomized Phase 2 Trial of Neoadjuvant and Adjuvant Therapy with the IRX-2 Regimen in Patients with Newly Diagnosed Stage II, III or IVA Squamous Cell Carcinoma of the Oral Cavity
    Medical condition: Newly Diagnosed Stage II, III or IVA Squamous Cell Carcinoma of the Oral Cavity.
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041857 Squamous cell carcinoma of the oral cavity PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) HU (Prematurely Ended) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-019952-35 Sponsor Protocol Number: CS001P3 Start Date*: 2010-09-14
    Sponsor Name:CEL-SCI Corporation
    Full Title: A Phase III, Open-label, Randomized, Multi-center Study of the Effects of Leukocyte Interleukin, Injection [Multikine] Plus Standard of Care (Surgery + Radiotherapy or Surgery + Concurrent Chemorad...
    Medical condition: Subjects with Advanced Primary Sqamous Cell Carcinoma of the oral Cavity/Soft Palate
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) PL (Completed) GB (GB - no longer in EU/EEA) AT (Prematurely Ended) RO (Ongoing) HR (Completed) ES (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2004-002016-28 Sponsor Protocol Number: 20040118 Start Date*: 2005-01-04
    Sponsor Name:Amgen
    Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Weekly Doses of Palifermin (Recombinant Human Keratinocyte Growth Factor, rHuKGF) for the Reduct...
    Medical condition: Oral mucositis
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004856 10028130 Mucositis oral LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) AT (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2018-003856-19 Sponsor Protocol Number: CVB2018-2 Start Date*: 2019-01-09
    Sponsor Name:Department of Otorhinolaryngology, Head and Neck Surgery and Audiology. Rigshospitalet, University Hospital of Cph, DK
    Full Title: A Phase I Open Label Study Evaluating the Safety and Feasibility of Allogeneic Mesenchymal stem cells for radiation-induced hyposalivation and xerostomia in previous oropharyngeal patients
    Medical condition: The trial will include participants with Xerostomia ( International Classification of Diseases-10: DQ 838A)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004856 10048223 Xerostomia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Nov 12 20:21:13 CET 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA